Last reviewed 2026-04-22 · How we verify

Motilitone® and Pantoline®

Motilitone enhances gastric muscle contractions and accelerates gastric emptying by acting as a dopamine antagonist and acetylcholinesterase inhibitor.

Motilitone enhances gastric muscle contractions and accelerates gastric emptying by acting as a dopamine antagonist and acetylcholinesterase inhibitor. Used for Functional dyspepsia, Gastric motility disorders.

At a glance

Mechanism of action

Motilitone (itzaura) works through dual mechanisms: it blocks dopamine receptors (which normally inhibit gastric contractions) and inhibits acetylcholinesterase (allowing acetylcholine to accumulate and enhance muscle contractions). This combination promotes coordinated gastric muscle activity and accelerates the movement of food from the stomach into the small intestine, improving gastric motility.

Approved indications

• Functional dyspepsia
• Gastroesophageal reflux disease (GERD)
• Postoperative gastric stasis

Common side effects

• Headache
• Dizziness
• Abdominal discomfort
• Nausea

Key clinical trials

• A Study to Demonstrate the Efficacy and Safety of Motilitone® (PHASE4)
• A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Motilitone® and Pantoline® CI brief — competitive landscape report
• Motilitone® and Pantoline® updates RSS · CI watch RSS
• Dong-A ST Co., Ltd. portfolio CI